Use of sodium‐glucose cotransporter‐2 inhibitors among older adults with type 2 diabetes mellitus in British Columbia
SGLT2i use among older adults with T2DM in British Columbia increased steadily from 2016 to 2022, followed by a spike in 2023, aligned with the expansion in publicly funded drug coverage. By the end of 2023, around one in five used SGLT2is, regardless of cardiorenal disease status.
Authors
- Lisa McCarthy (ORCID: https://orcid.org/0000-0001-9087-1077)
- Anshula Ambasta (ORCID: https://orcid.org/0000-0003-0211-8654)
- Wade Thompson (ORCID: https://orcid.org/0000-0002-8268-4092)
- Guillaume Grenet (ORCID: https://orcid.org/0000-0002-5237-2581)
- Greg Carney (ORCID: https://orcid.org/0000-0002-7438-5172)
- Anton Pottegård (ORCID: https://orcid.org/0000-0001-9314-5679)
- Colin R. Dormuth (ORCID: https://orcid.org/0000-0001-8577-8783)
- Jacob V. Stidsen (ORCID: https://orcid.org/0000-0003-2711-5927)
- Iliana Carolina Lega (ORCID: https://orcid.org/0000-0003-4816-2589)
- Hanin Harbi (ORCID: https://orcid.org/0009-0004-3776-6541)
- Raha Eskandari
Institutions
- Steno Diabetes Centers (DK)
- University of British Columbia (CA)
- University of Southern Denmark (DK)
- University of Toronto (CA)
- Trillium Health Centre (CA)
- Odense University Hospital (DK)
- Women's College Hospital (CA)
- Institute for Clinical Evaluative Sciences (CA)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1111/dom.70375
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00